Last reviewed · How we verify
Precocious puberty — Treatment Landscape & Competitive Intelligence
5 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Synarel | NAFARELIN | Pfizer | Gonadotropin Releasing Hormone Receptor Agonist | Gonadotropin-releasing hormone receptor | 1990-01-01 | |
| Lupron | leuprorelin | Accord Healthcare S.L.U. | Gonadotropin Releasing Hormone Receptor Agonist | GnRH receptors | 1985-01-01 | |
| Lupron | leuprolide | Accord Healthcare S.L.U. | Gonadotropin Releasing Hormone Receptor Agonist | Gonadotropin-releasing hormone receptor | 1985-01-01 | |
| Leuprolide Acetate | leuprolide-acetate | Pfizer | leuprorelin | Gonadotropin-releasing hormone receptor | 1985-01-01 | |
| Eligard | Eligard | Astellas Pharma Europe Ltd. | Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Accord Healthcare S.L.U. · 2 drugs in Precocious puberty
- Pfizer · 2 drugs in Precocious puberty
- · 1 drug in Precocious puberty
- Astellas Pharma Europe Ltd. · 1 drug in Precocious puberty
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Precocious puberty:
- Precocious puberty treatment updates — RSS
- Precocious puberty treatment updates — Atom
- Precocious puberty treatment updates — JSON
Cite this brief
Drug Landscape (2026). Precocious puberty — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/precocious-puberty. Accessed 2026-06-10.
Related
- Precocious puberty full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing